Free Trial
NASDAQ:CARM

Carisma Therapeutics 5/11/2023 Earnings Report

Carisma Therapeutics logo
$0.22 +0.00 (+2.23%)
As of 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Carisma Therapeutics EPS Results

Actual EPS
-$1.93
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Carisma Therapeutics Revenue Results

Actual Revenue
$3.24 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Carisma Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Carisma Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Carisma Therapeutics Earnings Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Carisma Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Carisma Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your email.

About Carisma Therapeutics

Carisma Therapeutics (NASDAQ:CARM), a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

View Carisma Therapeutics Profile

More Earnings Resources from MarketBeat